OnDemand WTP Pricing Research

Drug transparency bill ignores role of insurers | The Register-Guard

Every month, I visit a Eugene pharmacy to buy insulin for my 11-year-old daughter. She has type 1 diabetes, which means her body no longer makes insulin. Without daily insulin injections, she will die.

On an Oregon Bronze Affordable Care Act insurance plan, I pay $274 per vial for insulin that cost $21 in 1996. I worry about the price. Oregonians, like other Americans with diabetes, are now making desperate choices to afford the insulin that keeps them alive.

State Rep. Rob Nosse, D-Portland, says House Bill 4005 — a drug-pricing transparency bill rushed through the Senate last Friday and now headed to Gov. Kate Brown for her signature — will help my daughter and other Oregonians who rely on prescription drugs. “We don’t know,” he tells us, why these drugs are so expensive, but he claims manufacturers alone can explain this mystery.

Except I do know why my daughter’s insulin is so expensive. The legal advocacy nonprofit organization I cofounded in 2015 — the Type 1 Diabetes Defense Foundation — researched, reported (http://bit.ly/2teKhVE) and sued on this issue throughout 2017. I know that insurers, not just manufacturers, are benefiting from high list prices.

Read complete article here:

Drug transparency bill ignores role of insurers | Opinion | Eugene, Oregon.